Researchers at Kanazawa University report a blood-based diagnostic approach that could make early pancreatic cancer screening more feasible and improve patient outcomes. Pancreatic ductal adenocarcinoma remains lethal in part because early-stage disease is rarely detected—only about 2–3% of diagnoses occur at an early enough stage for curative surgery. In Japan, the five-year relative survival rate […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.